Active Ingredient History
Canakinumab, sold under the brand name Ilaris, is a medication for the treatment of systemic juvenile idiopathic arthritis and active Still's disease, including adult-onset Still's disease. It is a human monoclonal antibody targeted at interleukin-1 beta. It has no cross-reactivity with other members of the interleukin-1 family, including interleukin-1 alpha. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Alzheimer Disease (Phase 2)
Anemia, Sickle Cell (Phase 2)
Aortic Aneurysm, Abdominal (Phase 2)
Arthritis (Phase 3)
Arthritis, Gouty (Phase 3)
Arthritis, Psoriatic (Phase 4)
Arthritis, Rheumatoid (Phase 4)
Atherosclerosis (Phase 3)
Atrial Fibrillation (Phase 2)
Behcet Syndrome (Phase 2)
Breast Neoplasms (Phase 1)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Carcinoma, Renal Cell (Early Phase 1)
Cardiovascular Diseases (Phase 2)
Chronic Urticaria (Phase 2)
Cognitive Dysfunction (Phase 2)
Coronavirus Infections (Phase 3)
COVID-19 (Phase 3)
Diabetes Mellitus (Phase 2)
Diabetes Mellitus, Type 1 (Phase 2)
Diabetes Mellitus, Type 2 (Phase 3)
Diabetic Retinopathy (Phase 1)
Dry Eye Syndromes (Phase 2)
Fever (Phase 3)
Glucose Intolerance (Phase 2)
Gout (Phase 3)
Healthy Volunteers (Phase 1)
Hepatitis, Alcoholic (Phase 2)
HIV (Phase 2)
Inflammation (Phase 2)
Insulin Resistance (Phase 2)
Leukemia, Myelomonocytic, Chronic (Phase 2)
Lung Neoplasms (Phase 2)
Melanoma (Phase 2)
Mucocutaneous Lymph Node Syndrome (Phase 2)
Muscular Dystrophy, Duchenne (Phase 1/Phase 2)
Mutation (Phase 2)
Myelodysplastic Syndromes (Phase 2)
Osteoarthritis (Phase 2)
Osteoarthritis, Knee (Phase 2)
Pancreatic Neoplasms (Phase 1)
Peripheral Arterial Disease (Phase 2)
Polymyalgia Rheumatica (Phase 2)
Prediabetic State (Phase 2)
Pulmonary Disease, Chronic Obstructive (Phase 1/Phase 2)
Pyoderma Gangrenosum (Phase 2)
Sarcoidosis, Pulmonary (Phase 2)
Schnitzler Syndrome (Phase 2)
Spondylarthritis (Phase 4)
Still's Disease, Adult-Onset (Phase 3)
Tuberculosis (Phase 2)
Urticaria (Phase 2)
Vasculitis (Phase 2)
Wet Macular Degeneration (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
